Regulatory News:
SpineGuard (FR0011464452 ALSGD) (Paris:ALSGD), an innovative company that deploys its DSG (Dynamic Surgical Guidance) sensing technology to secure and streamline the placement of bone implants, announced today its revised schedule for the publication of financial information for 2022.
Revised 2022 financial calendar
Event | Date* |
2021 Full-Year Sales | January 26, 2022 |
2021 Full-Year Results | April 28, 2022 (vs. April 20, 202) |
2022 First-Quarter Sales | April 28, 2022 (vs. April 20, 202) |
Annual Shareholders Meeting | June 8, 2022 |
2022 First-Half Sales | July 12, 2022 |
2022 First-Half Results | September 14, 2022 |
2022 Third-Quarter Sales | October 12, 2022 |
Note (*): Press releases are published after stock market closes. This information is subject to modification.
About SpineGuard
Founded in 2009 in France and the USA by Pierre Jérôme and Stéphane Bette, SpineGuard is an innovative company deploying its proprietary radiation-free real time sensing technology DSG (Dynamic Surgical Guidance) to secure and streamline the placement of implants in the skeleton. SpineGuard designs, develops and markets medical devices that have been used in over 85,000 surgical procedures worldwide. Nineteen studies published in peer-reviewed scientific journals have demonstrated the multiple benefits DSG offers to patients, surgeons, surgical staff and hospitals. Building on these strong fundamentals and several strategic partnerships, SpineGuard has expanded the scope of its DSG technology in innovative applications such as the smart pedicle screw, the DSG Connect visualization and registration interface, dental implantology and surgical robotics. DSG was co-invented by Maurice Bourlion, Ph.D., Ciaran Bolger, M.D., Ph.D., and Alain Vanquaethem, Biomedical Engineer. SpineGuard has engaged in multiple ESG initiatives.
For further information, visit www.spineguard.com
Disclaimer:
The SpineGuard securities may not be offered or sold in the United States as they have not been and will not be registered under the Securities Act or any United States state securities laws, and SpineGuard does not intend to make a public offer of its securities in the United States. This is an announcement and not a prospectus, and the information contained herein does and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in the United States in which such offer, solicitation or sale would be unlawful prior to registration or exemption from registration.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220325005165/en/
Contacts:
SpineGuard
Pierre Jérôme
CEO Chairman
Tel: +33 1 45 18 45 19
p.jerome@spineguard.com
SpineGuard
Manuel Lanfossi
CFO
Tel: +33 1 45 18 45 19
m.lanfossi@spineguard.com
NewCap
Investor Relations Financial Communication
Mathilde Bohin Pierre Laurent
Tel.: +33 1 44 71 94 94
spineguard@newcap.eu
